Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding insider transactions rather than a financial performance report.
Material Changes
The filing discloses a specific transaction involving an increase in the notional allocation of GSK American Depositary Shares (ADSs) on May 22, 2015. The transaction occurred at a price of $45.26 per ADS and resulted from the revaluation of the cash element of a notional investment held within the GSK 401K plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Key Facts for Investor Verification
- Transaction Date: May 22, 2015.
- Connected Person: Dr K Slaoui (connected person of Dr M M Slaoui).
- Transaction Type: Increase in notional allocation of ADSs.
- Quantity: 4 ADSs.
- Price: $45.26 per ADS.
- Context: Revaluation of cash element within the GSK 401K plan.